You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康諾亞-B(02162.HK)公佈中期業績 研發開支大增378.41% 產品管線取得顯著進展
格隆匯 08-31 20:29

格隆匯8月31日丨康諾亞-B(02162.HK)公佈中期業績,截至2021年6月30日止6個月,研發開支由截至2020年6月30日止六個月的人民幣3990萬元增加人民幣1.511億元至截至2021年6月30日止六個月的人民幣1.91億元。此增加乃主要由於僱員薪酬及正在進行的管線產品臨牀前及臨牀研究增加所致。

行政開支由截至2020年6月30日止六個月的人民幣770萬元增加人民幣1910萬元至截至2021年6月30日止六個月的人民幣2680萬元。此增加乃主要由於僱員薪酬及與首次公開發售有關的專業服務費增加所致。

於2021年7月8日,公司於聯交所成功上市。自上市以來,公司在產品管線及業務運營方面取得了以下進展:

●  於2021年7月,公司就在中國開展用於治療復發或難治性非霍奇金淋巴瘤(NHL)的CM355的臨牀試驗申請已提交予國家藥監局並獲受理。

●  於2021年8月,公司向國家藥監局提交用於治療中重度兒童及青少年特應性皮炎的CM310的臨牀試驗申請。

●  於2021年8月,公司用於治療中重度特應性皮炎及慢性鼻竇炎伴鼻息肉的CM326的臨牀試驗申請已提交予國家藥監局並獲受理。

●  於2021年8月,公司用於治療IgA腎病的CM338的臨牀試驗申請已提交予國家藥監局並獲受理。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account